Kornimate/medical-research-clean huggingface dataset:
calcium electroporation for the treatment of colorectal cancer

Conditions: Colorectal Cancer Stage IV

Summary: in this phase i study 6 patients with inoperable colorectal cancer is treated with calcium electroporation to establish safety and efficacy of the treatment.

a total of 6 evaluable patients with inoperable colorectal cancer are expected to be included in the study and the time for inclusion of patients is estimated to be 1-2 years. all patients will have been offered the standard of care and all available alternatives before entering the protocol. calcium electroporation will not be compared to other means of treatment. all patients will be treated once, but in case of residual tumor tissue at follow-up, and if the investigator considers it safe, they will be offered re-treatment. a maximum of 3 treatments per patient will be conducted with an interval of minimum 4 weeks. the patients will be followed with regular examinations for 12 months, starting from first treatment day.

Eligibility criteria:
inclusion criteria: * histologically verified colorectal tumor * conferred by multidisciplinary team (radiologists, surgeons and oncologists) discussing options possible for the patient, resulting in agreement that an endoscopic treatment with calcium electroporation should be offered to the patient. * treatment free interval of minimum 2 weeks. * thrombocytes ≥ 50 billions/l, inr \>1,2. medical correction is allowed, e.g. correction of elevated inr by means of vitamin k. * performance status ecog/who ≤2 * both men and women who are sexually active must use safe contraception (contraceptive coil, deposit injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch.) * trial subject ≥ 18 years. * trial subject must be able to understand the participants' information. * signed informed consent. the patients are considered participants in the study after signing of the informed consent. exclusion criteria: * coagulative disturbance that cannot be corrected * pregnancy or lactation (pregnancy is ruled out in fertile women by an hcg test in a blood sample) * concurrent participation in other clinical trials that involve experimental drugs or participation in a clinical trial involving experimental drugs within 4 weeks prior to administration of the drug in this study. * treatment with bevacizumab within the last 4 weeks. * heavily inflamed colorectal mucus membrane with bleeding or ulcerations. * implanted colon stent * other clinical disease or previous treatments that make the investigator deem the patient unfit.
default mode network in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the study will evaluate connectivity regardless whether patients present a clinical type that requires medical treatment. in this point, investigators will include patients with progressive evolution as well as initial forms of the disease (cis) and properly established forms of multiple sclerosis (ms) in remittent-recidivant (rr) forms. the researches will not focus on medical treatment as some of these clinical forms have no indication for disease modifying drugs.

to date, no clear consensus has been reached related to default mode network (dmn) activity and different clinical types of ms. due to this controversy on the literature regarding increment and decrement of dmn activity along the natural history of ms evolution, this study aim to add experimental information and more data that might help to disentangle this paradox, also correlating this dmn activity with anatomic and cognitive indexes. the investigators will also introduce a novel experimental design, including a prospective measure of the investigators connectivity and cognitive measures. in this study, investigators aim to evaluate connectivity regardless whether patients present a clinical type that requires medical treatment. in this point, patients with progressive evolution as well as initial forms of the disease (cis) will be included and properly established forms of ms in rr forms. researchers will not focus on medical treatment as some of these clinical forms have no indication for disease modifying drugs. nevertheless, investigators consider that the study of connectivity is worth regardless their pharmacological treatment. the investigators also aim to offer data on the natural history of ms evolution for distinct ms type patients and healthy controls, as this study is planned to collect data longitudinally.

Eligibility criteria:
inclusion criteria: * ms diagnostic following mcdonald 2010 diagnosis criteria. * 18 to 60 years old. * consent form signature. exclusion criteria: * dementia diagnosis, following spanish neurological society criteria. * mayor psychiatric illness. * physical or intellectual limitations to successfully perform - neuropsychological evaluation. * any other circumstance that may interfere with functional magnetic resonance session. * abnormal renal function previous to magnetic resonance image (mri) session.
effect of treatment of temporomandibular joint in patients with chronic migraine and temporomandibular disorders

Conditions: Chronic Migraine; Temporomandibular Disorders

Summary: the aim of this study is to determine whether treatment of temporomandibular joint is more effective than usual care in patients with chronic migraine and temporomandibular disorders to reduce pain.

the aim of this study is to determine whether treatment of temporomandibular joint added to the control group treatment and drug therapy patient base is more effective than just using the control group treatment and drug therapy in patients with chronic migraine and temporomandibular disorders to reduce pain and improve the quality of life related to health of patients.

Eligibility criteria:
inclusion criteria: * chronic migraine (ichd_iii beta, 2013) * temporomandibular disorders (rdc/tmd) exclusion criteria: * other neurological disease * psychiatric diseases * physical therapy treatment in the last 6 months * dental treatment in the last 6 months * surgery or trauma in the orofacial region

Keywords: chronic migraine temporomandibular disorders physical therapy manual therapy home physical therapy
echinaforce junior bioavailability trial

Conditions: Common Cold

Summary: in this bioavailability trial should be shown that the one of the main active constituent in alcoholic echinacea extracts, the alkylamide dodeca-2e,4e,8z,10e/z-tetraenoic acid isobutylamide (short: tetraen) is bioavailable in children of different age groups after intake of 5 echinaforce junior tablets.

in this bioavailability trial should be shown that the one of the main active constituent in alcoholic echinacea extracts, the alkylamide dodeca-2e,4e,8z,10e/z-tetraenoic acid isobutylamide (short: tetraen) is bioavailable in children of different age groups after intake of 5 echinaforce junior tablets. six capillary blood draws are taken at the following time points: start (0), after 15, 30, 60, 90, 270 minutes and thereafter the bioavailability is measured and calculated.

Eligibility criteria:
inclusion criteria: * children in the age group 4-12 years with an uncomplicated common cold (upper respiratory tract infection) * first symptoms appeared within the last 72 hours * written consent given by the parents and verbal consent of children who are capable of judgement exclusion criteria: * not able to fast 2 hours prior to the treatment * intake of another preparation containing echinacea within the last 24 hours * participation in a clinical trial within the last 30 days * any progressive systemic illness, including tuberculosis, leukemia, connective tissue diseases, multiple sclerosis, or other autoimmune diseases; or * history of relevant allergy, including allergy to compositae plants

Keywords: echinacea bioavailability children
long term outcomes following total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy

Conditions: Total Laparoscopic Hysterectomy; Laparoscopic Supracervical Hysterectomy; Fibromas; Abnormal Uterine Bleeding; Dysmenorrhea

Summary: objective: to compare the occurrence and intensity of pelvic pain as well as patient satisfaction and quality of life after total laparoscopic and laparoscopic supracervical hysterectomy. design: prospective randomised trial. null hypothesis 1: there is no significant difference in occurrence and intensity of pelvic pain following tlh compared with following lsh. null hypothesis 2: there is no significant difference in patient satisfaction and quality of life following tlh compared with following lsh.

sample: 62 consecutive premenopausal women referred to the department for hysterectomy on the basis of a benign condition. the expected mean pain reduction (m) in the lsh group: 3.32, sd (s): 2.71.24 a difference in mean pain reduction (d) equal to 1 sd is considered a clinically important improvement (standardised difference d/s=1). number of women required (power 90 % and a level of significance 0.05): 62 patients. methods: the study participants are randomised to total laparoscopic hysterectomy (n = 31), or laparoscopic supracervical hysterectomy (n = 31).

Eligibility criteria:
inclusion criteria: * premenopausal women who are referred to the department * benign condition requiring hysterectomy * dysmenorrohea/cyclic pelvic pain * informed consent exclusion criteria: * women who are unable to communicate in norwegian language. * women with a previous history of cervical dysplasia, with cellular changes suggestive of dysplasia in preoperative cervical smear. * women with atypical hyperplasia or malignancy in preoperative endometrial biopsy. * women with a substantially enlarged uterus requiring abdominal hysterectomy or not suitable for tlh (\> 12 week amenorrhea). * women with a concomitant condition requiring uni- or bilateral oophorectomy. * postmenopausal women. * women with no dysmenorrohea/cyclic pelvic pain (\<1 on a 10-point visual analogue scale). * women with deep infiltrating endometriosis.

Keywords: total laparoscopic hysterectomy laparoscopic supracervical hysterectomy
study of dasatinib in patients with advanced solid tumors

Conditions: Tumors

Summary: the purpose of segment 1 of the study is to determine the effect of ketoconazole on dasatinib. the purpose of segment 2 is to learn how dasatinib affects tumor growth in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * ecog status 0-2 * advanced or metastatic disease, unresponsive to standard treatment (or no standard treatment exists) * biopsy pretreatment * adequate bone marrow, liver and kidney function exclusion criteria: * serious cardiovascular disease * bleeding disorders * gastrointestinal (gi) tract disease * platelet inhibitors * h2 blockers, proton pump inhibitors

Keywords: advanced solid tumors
effectiveness of physical therapy interventions for low back pain targeting the low back only or low back plus hips

Conditions: Low Back Pain; Hip Disease

Summary: low back pain (lbp) is the leading cause of disability worldwide and has substantial impacts on pain and function for an individual. some individuals with lbp seek physical therapy for their condition. the purpose of the study is to determine whether individuals with lbp have improved pain and disability following physical therapy targeting either the low back only or low back plus hip(s).

often, individuals with lbp also have concurrent impairments in strength and/or range of motion of one or both hips. physical therapists may or may not decide to treat the concurrent hip impairments for an individual with lbp based on their clinical decision making. currently, it is unknown which approach leads to superior patient outcomes in terms of pain and disability.

Eligibility criteria:
inclusion criteria: * modified oswestry disability index (odi) ≥ 20% * numeric pain rating scale (nprs) of ≥ 2 points * primary complaint of low back pain with at least one hip impairment in one or both hips exclusion criteria: * contraindications to manual therapy * severe trauma to the lumbar spine or hip(s) in the last 6 weeks * 'red flag' symptoms including: * tumor * metabolic disease * rheumatoid arthritis or other systemic rheumatologic disorders * acute fracture * bowel/bladder dysfunction * prolonged history of corticosteroid use * evidence of central nervous system involvement * two or more positive neurologic signs consistent with nerve root compression: * diminished muscle stretch reflexes of lower extremity * muscle weakness in any lower extremity myotome * diminished or absent sensation in any lower extremity dermatome * spinal surgery in the last 6 months * total hip arthroplasty * currently pregnant or post-partum ≤ 6 months * osteoporosis * history of cancer within the last 12 months * inability to understand the english language

Keywords: low back pain hip physical therapy
market penetration of laser therapy in venous surgery: ziekenhuis oost-limburg - ziekenhuis maas en kempen center experience

Conditions: Varicose Veins

Summary: the goal of this registry is to evaluate the indication for endovenous laser ablation (evla) therapy. can this be enhanced? what are the reasons for not using the laser? therefore, this study aims to define clear indications for evla by registering the incentives of the participating investigators to use the laser instead of conventional corrective surgery for the treatment of varicose veins, at baseline and post-operative. additionally, the efficacy and safety of the different varicose vein treatments will be evaluated by registering procedural characteristics, anatomic outcome (duplex ultrasound), quality of life (avvq) and postoperative pain (vas).


Eligibility criteria:
inclusion criteria: 1. patient is at least 18 years old. 2. patient must sign and date the informed consent form prior to treatment. 3. presence of unilateral or bilateral primary or recurrent symptomatic varicose veins (ceap grade ≥ c2). 4. patient has an insufficient great saphenous vein (gsv), anterior accessory saphenous vein (aasv) and/or small saphenous vein (ssv), with venous symptoms (valve incompetence). exclusion criteria: 1. current deep vein thrombosis. 2. acute superficial thrombosis. 3. pregnancy. 4. coagulopathy or bleeding disorders. 5. contraindications to the use of general or regional anesthesia.
to study the changes in protein in lung cells of asian patients with advanced non-small cell lung cancer (nsclc)

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is to study the changes in protein in lung cells of asian patients with advanced non small cell lung cancer.

a molecular epidemiology study in asian patients with advanced nsclc of adeno histology to assess egfr mutation status.

Eligibility criteria:
inclusion criteria: * histological or cytologically confirmed advanced non small cell lung cancer of adeno histology nsclc treatment naive availability of cancer tissue or cytology sample exclusion criteria: * involvement in the planning and/or conduct of the study previous enrollment in the present study

Keywords: nsclc, egfr mutation
patient- and family-centred care in the adult intensive care unit: a feasibility study

Conditions: Delirium; Anxiety; Post Intensive Care Unit Syndrome; Post Intensive Care Unit Syndrome Family; Depression; Posttraumatic Stress Disorder (PTSD); Mortality; Length of ICU Stay; Pain; Satisfaction Survey

Summary: background: in the intensive care unit (icu), delirium in patients and long-term mental health challenges in both patients and their family members are highly prevalent. to address these issues, patient- and family-centered care has been recommended to alleviate the burdens associated with critical illness and icu admission. we have developed the patient- and family-centered care in the adult icu intervention (fam-icu intervention). this multi-component intervention comprises several concrete and manageable components and operationalizing patient- and family-centered care principles in clinical practice. in this protocol, we describe a study aiming to evaluate the feasibility and acceptability of the fam-icu intervention in the adult icu setting, including the feasibility of collecting relevant patient- and family-member outcome data. referenc: bohart et al. 2024. acta anaesthesiol scand . 2025 jan;69(1):e14539. doi: 10.1111/aas.14539. epub 2024 oct 24. method: we will conduct a pre-/post two-group study design. we plan to recruit 30 adult icu patients and their close family members at herlev university hospital in denmark. the pre-group (n = 15) will receive usual care and the post-group (n = 15) will receive the fam-icu intervention. the fam-icu intervention involves interdisciplinary training of the icu team and a systematic approach to information sharing and consultations with the patients and their family. feasibility outcomes will include recruitment and retention rates, intervention fidelity, and the feasibility of participant outcome data collection. acceptability will be assessed through questionnaires and interviews with clinicians, patients, and family members. data collection is scheduled to begin in january 2025. discussion: this study will assess the feasibility and acceptability when implementing the fam-icu intervention and the feasibility of conducting a main trial to investigate its effectiveness on delirium in patients and the mental health of patients and family members. the data from the feasibility study will be used to guide sample size calculations, trial design, and final data collection methods for a subsequent stepped-wedge randomized controlled trial.


Eligibility criteria:
patients are eligible if they are: * ≥18 years of age. * expected to require icu admission for at least 48 hours in a mixed surgical and medical icu for adult critically ill patients. family members are eligible if they are: * ≥18 years of age. * a close family member to a patient-enrolled in the fam-icu. a family-member can be blood-related or not. it may be a spouse, relative, partner, or friend as determined by the patient as a close family member.

Keywords: patient- and family-centerede care feasibility icu
efficacy and safety of sr58611a co-administered with escitalopram in adults with major depressive disorder

Conditions: Major Depressive Disorder

Summary: the primary objective of the study is to compare, after 8 weeks, the efficacy of sr58611a vs. placebo in patients with major depressive disorder who are on concomitant treatment with escitalopram. the secondary objective of this study is to document clinical safety and tolerability of sr58611a in association with escitalopram.


Eligibility criteria:
inclusion criteria: * inpatients or outpatients with major depressive disorder characterized by a recurrent major depressive episode with montgomery and asberg depression rating scale (madrs) total score =\> 30 exclusion criteria: * patient is at immediate risk for suicidal behavior * patient with psychotic features, catatonic features, seasonal pattern or postpartum onset * patients with a current depressive episode secondary to a general medical disorder * patients with a lifetime history or presence of bipolar disorder, psychotic disorder, panic disorder and antisocial personality disorder * patients with severe or unstable concomitant medical conditions * pregnant, breastfeeding, or likely to become pregnant during the study * treated with escitalopram within 6 months before the study, or who have had an adverse reaction to escitalopram the investigator will evaluate whether there are other reasons why a patient may not participate.

Keywords: mental disorder mood disorder depressive disorder
family lifestyle actions and risk education study

Conditions: Melanoma; Child

Summary: the overall purpose of this study is to test the feasibility, acceptability, and preliminary efficacy of a family-focused behavioral intervention ("flare", which stands for family lifestyle actions and risk education) that aims to improve adherence to melanoma preventive behaviors among children at elevated risk for the disease.

test the feasibility and acceptability of flare, a family-focused behavioral intervention that is designed to improve and maintain adherence to photoprotection (e.g., use of sunscreen) and screening (e.g., implementation of self skin exams). we expect that the feasibility of the intervention will be supported by at least 75% of participants attending at least 3 intervention sessions. we also expect that the acceptability of the intervention (e.g., overall satisfaction, ease of participation, perceived utility of intervention) will be supported by mean ratings that indicate adequate levels of acceptability across participants (e.g., mean rating of "satisfied" or "very satisfied" for overall satisfaction). pilot test the efficacy of the flare intervention with children at elevated risk for melanoma and their primary caregiver. we will also explore the potential impact of the flare intervention on melanoma preventive behaviors among siblings of the child who receives the intervention, as well as the child's other parent/caregiver (if another parent/caregiver is available).

Eligibility criteria:
inclusion criteria: children * are 8-17 years old and * are at risk for melanoma due to having a first degree relative with a history of melanoma and/or at least 3 second or third degree relatives on the same side of the family with a history of melanoma and/or * have personally received genetic testing for the cdkn2a/p16 genetic mutation and/or has one or more family members who received cdkn2a/p16 testing adults * are at least 18 years old and * are the primary caregiver for the child participating in the study (defined as the individual who is responsible for daily implementation of health-related tasks for the child) and * have at least one child under age 18 who is living in the same household and * have a personal history of melanoma and/or family history of melanoma) and/or * have personally received genetic testing for the cdkn2a/p16 genetic mutation and/or has one or more family members who received cdkn2a/p16 testing exclusion criteria: * individuals who do not speak, read/write english will be excluded because flare involves regular interaction between study staff and research participants in english and completion of study questionnaires and interviews in english

Keywords: education prevention and control behavioral research
global prevalence of attr-cm in participants with hfpef

Conditions: Transthyretin Amyloid Cardiomyopathy; Heart Failure With Preserved Ejection Fraction

Summary: this study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (attr-cm) within a clinically at risk population \[participants with heart failure with preserved ejection fraction (hfpef)\].


Eligibility criteria:
inclusion criteria: 1. medical history of heart failure (hf) with: 1. at least 1 episode with clinical evidence of hf (without hospitalization) by signs or symptoms of volume overload or elevated intracardiac pressures that required/requires treatment with a diuretic for improvement; or 2. 1 prior hospitalization for hf. 2. left ventricular ejection fraction (lvef) \>40%. 3. end-diastolic interventricular septal wall thickness (ivst) ≥12 mm. 4. willing and able to undergo scintigraphy. exclusion criteria: 1. diagnosis of heart failure with reduced ejection fraction (hfref) (ef ≤40%). 2. prior clinical history of myocardial infarction, cabg or multi-vessel obstructive coronary disease (\>50% stenosis of ≥2 epicardial coronary arteries). 3. presence or history of any severe valvular heart disease (obstructive or regurgitant). 4. a confirmed diagnosis of a non-amyloid infiltrative cardiomyopathy (ie, cardiac sarcoidosis, hemochromatosis), muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy with known genetic etiology, or known pericardial constriction. 5. any type of diagnosed amyloidosis (eg, amyloid a amyloidosis, primary \[light chain\] amyloidosis) or prior diagnosis of attr-cm. -

Keywords: prevalence transthyretin amyloid attr-cm hfpef scintigraphy